335 results on '"Sorio, Roberto"'
Search Results
2. A TGF-β associated genetic score to define prognosis and platinum sensitivity in advanced epithelial ovarian cancer
3. Prognostic role of chemotherapy-induced neutropenia in first-line treatment of advanced ovarian cancer. A pooled analysis of MITO2 and MITO7 trials
4. Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial
5. Patient-Reported Outcome Results From the Open-Label Phase III AURELIA Trial Evaluating Bevacizumab-Containing Therapy for Platinum-Resistant Ovarian Cancer
6. Supplementary Figure S1 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
7. Supplementary Table S2 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
8. Data from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
9. Supplementary Appendix S1 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
10. Safety and efficacy of single-agent bevacizumab-containing therapy in elderly patients with platinum-resistant recurrent ovarian cancer: Subgroup analysis of the randomised phase III AURELIA trial
11. Human epidermal growth factor receptor-2 (HER2) is a potential therapeutic target in extramammary Paget’s disease of the vulva
12. Machine Learning Application Identifies Germline Markers of Hypertension in Ovarian Cancer Patients Treated with Carboplatin, Taxane and Bevacizumab
13. Carboplatin and paclitaxel plus avelumab compared with carboplatin and paclitaxel in advanced or recurrent endometrial cancer (MITO END-3): a multicentre, open-label, randomised, controlled, phase 2 trial
14. Development and validation of a microRNA-based signature (MiROvaR) to predict early relapse or progression of epithelial ovarian cancer: a cohort study
15. Machine Learning Application Identifies Germline Markers of Hypertension in Patients With Ovarian Cancer Treated With Carboplatin, Taxane, and Bevacizumab.
16. TP033/#1441 MITO 25.1: a randomized, molecular driven phase II trial of carboplatin-paclitaxel-bevacizumab vs carboplatin-paclitaxel-bevacizumab-rucaparib vs carboplatin-paclitaxel-rucaparib, selected according to HRD status, in patients with advanced ovarian cancer
17. CDK6 protects epithelial ovarian cancer from platinum‐induced death via FOXO3 regulation
18. Emesis and nausea related to single agent trabectedin in ovarian cancer patients: a sub-study of the MITO15 project
19. 2022-RA-1540-ESGO MITO 25.1: a randomized, molecular driven phase II trial of carboplatin-paclitaxel-bevacizumab vs carboplatin-paclitaxel-bevacizumab-rucaparib vs carboplatin-paclitaxel-rucaparib, selected according to HRD status, in patients with advanced (Stage III B-C-IV) ovarian, primary peritoneal and fallopian tube cancer
20. Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial
21. An Exceptional Response to Dostarlimab in Mismatch Repair Deficient, Microsatellite Instability-High and Platinum Refractory Endometrial Cancer
22. Breast cancer incidence in patients with BRCA-related advanced ovarian cancer receiving olaparib-based maintenance therapy: A pooled analysis from phase III clinical trials.
23. A microRNA signature defines chemoresistance in ovarian cancer through modulation of angiogenesis
24. CDK6 protects epithelial ovarian cancer from platinum‐induced death via FOXO3 regulation
25. Fertility-sparing treatment for serous borderline ovarian tumors with extra-ovarian invasive implants: Analysis from the MITO14 study database
26. Inhibition of CDK4/6 as Therapeutic Approach for Ovarian Cancer Patients: Current Evidences and Future Perspectives
27. Weekly paclitaxel in heavily pretreated ovarian cancer patients: does this treatment still provide further advantages?
28. A phase II study of capecitabine in the treatment of ovarian cancer resistant or refractory to platinum therapy: a multicentre Italian trial in ovarian cancer (MITO-6) trial
29. Population Pharmacokinetics and Pharmacodynamics of Doxorubicin and Cyclophosphamide in Breast Cancer Patients: A Study by the EORTC-PAMM-NDDG
30. A phase II study of sabarubicin (MEN-10755) as second line therapy in patients with locally advanced or metastatic platinum/taxane resistant ovarian cancer
31. A European, Observational, Prospective Trial of Trabectedin Plus Pegylated Liposomal Doxorubicin in Patients with Platinum-Sensitive Ovarian Cancer
32. CDKN1Bmutation and copy number variation are associated with tumor aggressiveness in luminal breast cancer
33. Phase II study of XR5000 (DACA), an inhibitor of topoisomerase I and II, administered as a 120-h infusion in patients with advanced ovarian cancer*
34. Carzelesin phase II study in advanced breast, ovarian, colorectal, gastric, head and neck cancer, non-Hodgkin's lymphoma and malignant melanoma: a study of the EORTC early clinical studies group (ECSG)
35. Revisiting the Clinical Value of 18F-FDG PET/CT in Detection of Recurrent Epithelial Ovarian Carcinomas: Correlation With Histology, Serum CA-125 Assay, and Conventional Radiological Modalities
36. Lapatinib-based therapy in heavily pretreated HER2-positive metastatic breast cancer: a single institution experience
37. Pharmacokinetics of oral etoposide in patients with hepatocellular carcinoma
38. Pharmacogenetic score predicts overall survival, progression-free survival and platinum sensitivity in ovarian cancer
39. Bevacizumab or PARP-Inhibitors Maintenance Therapy for Platinum-Sensitive Recurrent Ovarian Cancer: A Network Meta-Analysis
40. TIMP-1 Is Overexpressed and Secreted by Platinum Resistant Epithelial Ovarian Cancer Cells
41. A centralized Pharmacy Unit for cytotoxic drugs in accordance with Italian legislation
42. Vinorelbine-induced Acute Reversible Peripheral Neuropathy in a Patient with Ovarian Carcinoma Pretreated with Carboplatin and Paclitaxel
43. THE IMPACT OF XRCC1 (ARG399GLN) POLYMORPHISM IN OVARIAN CANCER CHEMOTHERAPY
44. Flavone acetic acid distribution in human malignant tumors
45. Carboplatin and Topotecan Combination and Myelosuppression
46. Population pharmacokinetics and pharmacodynamics of oral etoposide
47. Multimodal treatment with sequential intra-arterial chemotherapy (SIC) and radical surgery (RS) in patients with advanced and recurrent cervical carcinoma (CC).
48. Metastatic Colorectal Cancer (COL) in elderly patients (PTS): efficacy and tolerability of Folfox2 Regimen
49. Chronic methotrexate (OMTX) with carboplatin (CBDCA) in advanced ovarian cancer (OC) patients (pts) and methylenetetrahydrofolate reductase (mthfr) as a genetic determinant for toxicity.
50. Clonal Evolution of TP53 c.375+1G>A Mutation in Pre- and Post- Neo-Adjuvant Chemotherapy (NACT) Tumor Samples in High-Grade Serous Ovarian Cancer (HGSOC)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.